HEPATOCELLULAR CANCER
Clinical trials for HEPATOCELLULAR CANCER explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CANCER trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to shrink liver tumors
Disease control TerminatedThis study tested a combination of three drugs—nivolumab, tadalafil, and vancomycin—in adults with liver cancer or liver tumors that spread from colorectal or pancreatic cancer. The goal was to see if the treatment could shrink tumors. The study was stopped early, but the results…
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients
Disease control TerminatedThis study tested a new drug called TAK-500, given alone or with another drug (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early…
Matched conditions: HEPATOCELLULAR CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
Cancer gene hunt: can DNA profiles tailor therapy for stomach and liver tumors?
Knowledge-focused TerminatedThis study looked at genetic mutations in tumors from 565 people with advanced cancers of the digestive system, including liver, pancreas, and stomach. The goal was to see how often these mutations occur and whether they can help doctors choose more personalized treatments. The s…
Matched conditions: HEPATOCELLULAR CANCER
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated May 17, 2026 00:52 UTC